SANDRA GAROFALO: Open Payments
NPI 1689221905 · LAFAYETTE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$11,887 in 78 payments from 29 companies in 2025. Trend: 2023 $1,441 · 2024 $9,297 · 2025 $11,887
Speaker / faculty: $6,235Travel & lodging: $2,841Food & beverage: $2,649Long term medical supply or device loan: $83Education: $78
| Company | Payments | Amount |
|---|---|---|
| JAZZ PHARMACEUTICALS INC. | 14 | $9,372 |
| Janssen Biotech, Inc. | 4 | $371 |
| Syndax Pharmaceuticals, Inc. | 3 | $313 |
| Amgen Inc. | 2 | $282 |
| Novartis Pharmaceuticals Corporation | 12 | $279 |
| Incyte Corporation | 3 | $259 |
| AstraZeneca Pharmaceuticals LP | 2 | $153 |
| ABBVIE INC. | 6 | $137 |
| SANOFI-AVENTIS U.S. LLC | 2 | $111 |
| PFIZER INC. | 4 | $66 |
Products named: ZIIHERA, RYBREVANT, KISQALI, REVUFORJ, IMDELLTRA (AMG757), Monjuvi, BLINCYTO, Jakafi.
Industry payments across IN — which companies pay providers there.
